Kohei Suzuyama

Kohei Suzuyama

Auto-generated profile, based on publicly available information

Kohei Suzuyama

Division of Neurology, Department of Internal Medicine, Saga University Faculty of Medicine, Saga, Japan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2020 in International Journal of Stroke
Verified
Journal Article
Closed access
PDF file
KSKohei Suzuyama
Kohei Suzuyama
YYYusuke Yakushiji
Yusuke Yakushiji
AOAtsushi Ogata
Atsushi Ogata
MNMasashi Nishihara
Masashi Nishihara
MEMakoto Eriguchi
Makoto Eriguchi
HHHideo Hara
Hideo Hara
We explored the association between the total small vessel disease score obtained from baseline magnetic resonance imaging and subsequent cerebro-cardiovascular events in neurologically healthy Japanese adults. The presence of small vessel disease features, including lacunae, cerebral microbleeds, white matter changes, and basal ganglia perivascular spaces on magnetic resonance imaging, was summed to obtain a “total small vessel disease score” (range, 0–4). After excluding participants with previous stroke or ischemic heart disease, intracranial artery stenosis (≥50%), or cerebral aneurysm (≥4 mm), a total of 1349 participants (mean age, 57.7 years; range, 22.8–85.0 years; 46.9% male) were classified into three groups by total small vessel disease score: 0 (n = 984), 1 (n = 269), and ≥2 (n = 96). Cerebro-cardiovascular events (i.e., any stroke, transient ischemic attack, ischemic heart disease, acute heart failure, and aortic dissection) were defined as the primary end point. The hazard ratio (HR) of events during follow-up was calculated using Cox proportional hazards modeling with adjustments for age, sex, hypertension, diabetes mellitus, and smoking. Cumulative event-free rates were estimated using the Kaplan–Meier method. During follow-up (mean, 6.7 years), 35 cerebro-cardiovascular (16 cerebrovascular) events were identified. Higher small vessel disease score was associated with increased risk of cerebro-cardiovascular events (HR per unit increase, 2.17; 95% confidence interval, 1.36–3.46; P = 0.001). Events were more frequent among participants with higher score (P < 0.001, log-rank test). This study offered additional evidence for the clinical relevance of total small vessel disease score, suggesting the score as a promising tool to predict the risk of subsequent vascular events even in healthy populations.

Verified
Journal Article
Open access
PDF file
YYYusuke Yakushiji
Yusuke Yakushiji
KKKazuhiro Kawamoto
Kazuhiro Kawamoto
KUKazuyoshi Uchihashi
Kazuyoshi Uchihashi
MIMasafumi Ihara
Masafumi Ihara
SAShigehisa Aoki
Shigehisa Aoki
HHHideo Hara
Hideo Hara
A previous study reported that relatively high-dose cilostazol (0.3%) promoted the drainage of cerebrovascular amyloid-β (Aβ) protein in Aβ Precursor Protein (APP) transgenic mice overexpressing vasculotropic Aβ. We investigated whether lower-dose cilostazol can decrease micro-hemorrhages and Aβ deposition in the brain using APP transgenic mice. At baseline, 14-month-old female Tg2576 mice were randomly assigned to a control group (vehicle), aspirin group (0.01% aspirin), or cilostazol group (0.01% cilostazol). The severity of cerebral micro-hemorrhages (i.e., number), area of senile plaque, and severity of vascular amyloid burden (quantified with cerebral amyloid angiopathy (CAA) score (=number of Aβ-positive vessels × severity of amyloid burden of Aβ-positive vessels) were evaluated in the brain of mice aged 15 and 21–23 months. At 15 months, no differences were shown in each pathological change among the three groups. At 21–23 months, there were no differences in the severity of cerebral micro-hemorrhages or area of senile plaque among the three groups. However, the CAA score was significantly lower in the cilostazol compared to the control group (p = 0.046, Mann–Whitney U test), although no difference was seen between the control and aspirin group. Our study showed that lower-dose cilostazol could reduce the vascular amyloid burden without increasing cerebral micro-hemorrhages in APP transgenic mice.

2 July 2026 in Geriatrics & Gerontology International
Verified
Journal Article
Closed access
MMMegumi Mizoguchi
Megumi Mizoguchi
SIShuhei Ikeda
Shuhei Ikeda
YYYusuke Yakushiji
Yusuke Yakushiji
MEMakoto Eriguchi
Makoto Eriguchi
JTJun Tanaka
Jun Tanaka
HKHaruki Koike
Haruki Koike

1 January 2024 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
KSKohei Suzuyama
Kohei Suzuyama
MEMakoto Eriguchi
Makoto Eriguchi
HMHiromu Minagawa
Hiromu Minagawa
HHHiroyuki Honda
Hiroyuki Honda
KKKeita Kai
Keita Kai
HHHideo Hara
Hideo Hara
Suzuyama K, et al. J Clin Neurol. 2024 Jan;20:e13. https://doi.org/10.3988/jcn.2023.0102